+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years +
All Genders
ID06696183

Study of Gilteritinib with Venetoclax and Azacitidine for Adults with Newly Diagnosed AML and FLT3 Mutations Who Cannot Have Intensive Chemotherapy

Led by Technische Universität Dresden · Updated on 2025-05-29

60

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the best tolerable and effective dose of Gilteritinib combined with standard treatments Venetoclax and Azacitidine in patients with newly diagnosed acute myeloid leukemia AML who have FLT3 mutations and cannot receive intensive chemotherapy. This Phase 2 trial focuses on patients ineligible for standard induction chemotherapy and aims to find the optimal dosing strategy for this combination. The study is led by Technische Universitt Dresden and evaluates how well these treatments can be delivered together over time. Participants receive one of four treatment schedules combining Gilteritinib, Venetoclax, and Azacitidine in different sequences and durations. Gilteritinib is given at 80 mg, Venetoclax at 400 mg, and Azacitidine at 75 mgm. The study groups vary by the days on which each drug is administered during a 28-day cycle, with Venetoclax given for either 7 or 14 days and Gilteritinib starting on day 1 or day 8. These schedules are designed to explore the best timing and dose combination for safety and effectiveness. During the study, participants are monitored for how much of the planned dose they receive over 12 months. Researchers assess treatment adherence and tolerability, tracking the ratio of dose delivered versus dose planned. The trial involves random assignment to one of the four treatment groups without masking. Participants undergo regular evaluations to monitor their health and response to treatment until the study ends in April 2030.

CONDITIONS

Brief Title

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment

Research Team

P

Prof. Dr. Christoph Röllig, MD, MSc

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here